Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates

doi:10.1126/science.abl8912

. 2021 Dec 10;374(6573):1343-1353.

doi: 10.1126/science.abl8912. Epub 2021 Oct 21.

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates

Kizzmekia S Corbett^#¹, Matthew Gagne^#¹, Danielle A Wagner¹, Sarah O' Connell¹, Sandeep R Narpala¹, Dillon R Flebbe¹, Shayne F Andrew¹, Rachel L Davis¹, Barbara Flynn¹, Timothy S Johnston¹, Christopher D Stringham¹, Lilin Lai², Daniel Valentin³, Alex Van Ry³, Zackery Flinchbaugh³, Anne P Werner¹, Juan I Moliva¹, Manjari Sriparna¹, Sijy O'Dell¹, Stephen D Schmidt¹, Courtney Tucker¹, Angela Choi⁴, Matthew Koch⁴, Kevin W Bock⁵, Mahnaz Minai⁵, Bianca M Nagata⁵, Gabriela S Alvarado¹, Amy R Henry¹, Farida Laboune¹, Chaim A Schramm¹, Yi Zhang¹, Eun Sung Yang¹, Lingshu Wang¹, Misook Choe¹, Seyhan Boyoglu-Barnum¹, Shi Wei¹, Evan Lamb¹, Saule T Nurmukhambetova¹, Samantha J Provost¹, Mitzi M Donaldson¹, Josue Marquez¹, John-Paul M Todd¹, Anthony Cook³, Alan Dodson³, Andrew Pekosz⁶, Eli Boritz¹, Aurélie Ploquin¹, Nicole Doria-Rose¹, Laurent Pessaint³, Hanne Andersen³, Kathryn E Foulds¹, John Misasi¹, Kai Wu⁴, Andrea Carfi⁴, Martha C Nason⁷, John Mascola¹, Ian N Moore⁵, Darin K Edwards⁴, Mark G Lewis³, Mehul S Suthar², Mario Roederer¹, Adrian McDermott¹, Daniel C Douek¹, Nancy J Sullivan¹, Barney S Graham¹, Robert A Seder¹

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
² Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
³ BIOQUAL Inc., Rockville, MD 20850, USA.
⁴ Moderna Inc., Cambridge, MA 02139, USA.
⁵ Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
⁶ Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA.
⁷ Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

^# Contributed equally.

PMID: 34672695
DOI: 10.1126/science.abl8912

Free article

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates

Kizzmekia S Corbett et al. Science. 2021.

Free article

. 2021 Dec 10;374(6573):1343-1353.

doi: 10.1126/science.abl8912. Epub 2021 Oct 21.

Authors

Affiliations

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
² Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA 30322, USA.
³ BIOQUAL Inc., Rockville, MD 20850, USA.
⁴ Moderna Inc., Cambridge, MA 02139, USA.
⁵ Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
⁶ Department of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA.
⁷ Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

^# Contributed equally.

PMID: 34672695
DOI: 10.1126/science.abl8912

Abstract

Neutralizing antibody responses gradually wane against several variants of concern (VOCs) after vaccination with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine messenger RNA-1273 (mRNA-1273). We evaluated the immune responses in nonhuman primates that received a primary vaccination series of mRNA-1273 and were boosted about 6 months later with either homologous mRNA-1273 or heterologous mRNA-1273.β, which encompasses the spike sequence of the B.1.351 Beta variant. After boost, animals had increased neutralizing antibody responses across all VOCs, which was sustained for at least 8 weeks after boost. Nine weeks after boost, animals were challenged with the SARS-CoV-2 Beta variant. Viral replication was low to undetectable in bronchoalveolar lavage and significantly reduced in nasal swabs in all boosted animals, suggesting that booster vaccinations may be required to sustain immunity and protection.

PubMed Disclaimer

Update of

Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates.
Corbett KS, Gagne M, Wagner DA, Connell SO, Narpala SR, Flebbe DR, Andrew SF, Davis RL, Flynn B, Johnston TS, Stringham C, Lai L, Valentin D, Van Ry A, Flinchbaugh Z, Werner AP, Moliva JI, Sriparna M, O'Dell S, Schmidt SD, Tucker C, Choi A, Koch M, Bock KW, Minai M, Nagata BM, Alvarado GS, Henry AR, Laboune F, Schramm CA, Zhang Y, Wang L, Choe M, Boyoglu-Barnum S, Shi W, Lamb E, Nurmukhambetova ST, Provost SJ, Donaldson MM, Marquez J, Todd JM, Cook A, Dodson A, Pekosz A, Boritz E, Ploquin A, Doria-Rose N, Pessaint L, Andersen H, Foulds KE, Misasi J, Wu K, Carfi A, Nason MC, Mascola J, Moore IN, Edwards DK, Lewis MG, Suthar MS, Roederer M, McDermott A, Douek DC, Sullivan NJ, Graham BS, Seder RA. Corbett KS, et al. bioRxiv [Preprint]. 2021 Aug 12:2021.08.11.456015. doi: 10.1101/2021.08.11.456015. bioRxiv. 2021. Update in: Science. 2021 Dec 10;374(6573):1343-1353. doi: 10.1126/science.abl8912. PMID: 34426813 Free PMC article. Updated. Preprint.

Cited by

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.
Rössler A, Netzl A, Knabl L, Schäfer H, Wilks SH, Bante D, Falkensammer B, Borena W, von Laer D, Smith DJ, Kimpel J. Rössler A, et al. Nat Commun. 2022 Dec 13;13(1):7701. doi: 10.1038/s41467-022-35312-3. Nat Commun. 2022. PMID: 36513653 Free PMC article.
SARS-CoV-2-specific CD4⁺ T cells are associated with long-term persistence of neutralizing antibodies.
Wang Z, Yang X, Mei X, Zhou Y, Tang Z, Li G, Zhong J, Yu M, Huang M, Su X, Lin B, Cao P, Yang J, Ran P. Wang Z, et al. Signal Transduct Target Ther. 2022 Apr 23;7(1):132. doi: 10.1038/s41392-022-00978-0. Signal Transduct Target Ther. 2022. PMID: 35461307 Free PMC article.
Phage Display-Derived Peptide for the Specific Binding of SARS-CoV-2.
Yang F, Liu L, Neuenschwander PF, Idell S, Vankayalapati R, Jain KG, Du K, Ji H, Yi G. Yang F, et al. ACS Omega. 2021 Dec 29;7(4):3203-3211. doi: 10.1021/acsomega.1c04873. eCollection 2022 Feb 1. ACS Omega. 2021. PMID: 35128233 Free PMC article.
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022.
Sridhar S, Chicz RM, Warren W, Tartaglia J, Savarino S, Gurunathan S, Toussaint JF. Sridhar S, et al. Nat Commun. 2022 Oct 2;13(1):5794. doi: 10.1038/s41467-022-33549-6. Nat Commun. 2022. PMID: 36184631 Free PMC article.
Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques.
Li P, Wang Q, He Y, Yang C, Zhang Z, Liu Z, Liu B, Yin L, Cui Y, Hu P, Liu Y, Zheng P, Wang W, Qu L, Sun C, Guan S, Feng L, Chen L. Li P, et al. Emerg Microbes Infect. 2023 Dec;12(1):e2136538. doi: 10.1080/22221751.2022.2136538. Emerg Microbes Infect. 2023. PMID: 36239345 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates

Affiliations

Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates

Authors

Affiliations

Abstract

Update of

Similar articles

Cited by

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Update of

Similar articles

Cited by

Publication types

MeSH terms

Substances

Supplementary concepts

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous